Hyperpolarized MRI Technology Resource Center

超极化 MRI 技术资源中心

基本信息

批准号：
8935683
负责人：
Daniel B Vigneron
金额：
$ 168.88万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-01 至 2021-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8935683
关键词：
2,4-Dinitrophenol Advisory Committees Algorithms Animal Model Animals Biochemical Pathway Bioreactors Cancer Patient Chemistry Clinical Clinical Research Communities Computer software Coupled Data Data Analyses Development Documentation Educational workshop Electronic Mail Extramural Activities Funding Future Goals Grant Human Image Imagery Imaging Techniques Institution International Investigation Magnetic Resonance Imaging Malignant neoplasm of prostate Methodology Methods Monitor Motivation Pathologic Patient Care Phase I Clinical Trials Positron-Emission Tomography Pre-Clinical Model Process Publications Research Research Infrastructure Research Personnel Resources Safety Science Services Site Software Tools Structure Techniques Technology Testing Training Training Support Training and Infrastructure Translating Translations United States National Institutes of Health Validation Visit Visualization software base data acquisition experience human disease imaging modality imaging probe improved instrumentation interest method development molecular imaging new technology novel open source pre-clinical public health relevance reconstruction research and development research study symposium technology development tool validation studies web site

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this P41 center is to disseminate optimal new hyperpolarized (HP) 13C MR technologies with optimal training/documentation to advance significantly this emerging molecular imaging method. Through our HP MR studies to date, it has become clear both that hyperpolarized 13C MR has outstanding research and clinical value, but also that virtually all aspects of this technology (instrumentation, agent chemistry, DNP/dissolution methodology, MR acquisition, and data analysis) are currently suboptimal and require focused technological development to realize their full potential. This center includes three Technology Research & Development (TR&D) projects led by experienced hyperpolarized MR researchers. All TR&D developments are driven in a push-pull manner by 10 independently NIH-funded Collaborative Projects (CP's) and the technology resources of the center will be utilized by 8 Service Projects (SP's) and disseminated to all interested investigators through hands-on workshops, visits, email, and via the HMTRC website. TR&D1, led by the PI Dr. Vigneron, is focused on DNP polarizer and MR acquisition development for pre-clinical animal studies and their translation for future human studies. TR&D2 led by Dr. Kurhanewicz focuses on the development of new robust and realistic pre-clinical models for HP MR studies, optimization of current HP probes & investigation of new HP probes, and the development of methods that provide appropriate correlative pathologic, biologic and other imaging data for understanding and validating HP MR findings. TR&D3 led by Dr. Nelson focuses on enhancing a free open-source specialized software platform for HP MR data reconstruction and visualization. In its first four years, the HMTRC has developed new polarization, MR acquisition, bioreactor, and analysis techniques driven by close interactions with the CP projects resulting in 70 publications and over 150 conference presentations. This BTRC has also spawned/supports currently more than 15 NIH grants including new ones for all 10 proposed CP's. Guided by an exceptional EAC, the HMTRC has created an extensive infrastructure that extends nationally and internationally to support the SP's and other collaborators, a new website, highly successful hands-on workshops, and other focused training and dissemination activities. Since the submission of the current P41, the first Phase 1 clinical trial in prostate cancer patients was conducted and demonstrated safety and feasibility of this emerging molecular imaging technique. Now, four of the Collaborative Projects include future human studies. Therefore we are modifying the structure and goals of the center to not only advance preclinical HP MR, but also to include new technology development, administrative infrastructure, training and dissemination to support and advance future human studies at UCSF and other institutions.

描述（由申请人提供）：该 P41 中心的总体目标是传播最佳的新型超极化 (HP) 13C MR 技术以及最佳的培训/文档，以显着推进这种新兴的分子成像方法。人们清楚地认识到，超极化 13C MR 具有出色的研究和临床价值，而且该技术的几乎所有方面（仪器、试剂化学、DNP/溶出方法、MR该中心包括由经验丰富的超极化 MR 研究人员领导的三个技术研发 (TR&D) 项目，所有 TR&D 开发均以推拉方式驱动。由 10 个 NIH 资助的合作项目（CP）和该中心的技术资源将由 8 个服务项目（SP）独立利用，并通过实践研讨会传播给所有感兴趣的研究人员， TR&D1 由 PI Vigneron 博士领导，专注于临床前动物研究的 DNP 偏振器和 MR 采集开发，以及由 Kurhanewicz 博士领导的未来人类研究的翻译。为 HP MR 研究开发新的稳健且现实的临床前模型、优化当前 HP 探针和研究新的 HP 探针，以及开发提供适当相关性的方法Nelson 博士领导的 TR&D3 致力于增强 HP MR 数据重建和可视化的免费开源专业软件平台，用于理解和验证 HP MR 结果。与 CP 项目的密切互动推动了新的极化、MR 采集、生物反应器和分析技术，产生了 70 篇出版物和 150 多个会议演示文稿，该 BTRC 目前还催生/支持了超过 15 个。 NIH 拨款包括为所有 10 个拟议 CP 提供的新拨款。在杰出的 EAC 的指导下，HMTRC 创建了广泛的基础设施，可在国内和国际范围内扩展，以支持 SP 和其他合作者、新网站、非常成功的实践研讨会和其他活动。自提交当前 P41 以来，在前列腺癌患者中进行了第一个 1 期临床试验，并证明了这种新兴分子成像技术的安全性和可行性。现在，其中四个合作项目包括。因此，我们正在修改该中心的结构和目标，不仅要推进临床前 HP MR，还要纳入新技术开发、管理基础设施、培训和传播，以支持和推进加州大学旧金山分校和其他机构的未来人类研究。